Varma A, Singh MP, Sah S, Verma A, et al. Commentary on 'DORA: 48-week weight and metabolic changes in black women with HIV, in a phase IIIb switch study from dolutegravir- or efavirenz- to doravirine-based first-line antiretroviral therapy'. HIV Med 2024 Dec 26. doi: 10.1111/hiv.13755.
PMID: 39726112